Allergic Bronchopulmonary Aspergillosis

Allergic Bronchopulmonary Aspergillosis (ABPA) is a complex hypersensitivity reaction to the fungus Aspergillus fumigatus that primarily affects individuals with asthma or cystic fibrosis. It is characterized by recurrent episodes of bronchial obstruction, inflammation, and lung damage, including bronchiectasis, due to an exaggerated immune response to Aspergillus antigens colonizing the airways. Untreated ABPA can lead to irreversible lung damage and respiratory compromise.

ABPA is caused by an immune-mediated inflammatory response to antigens from the ubiquitous fungus Aspergillus fumigatus. The fungus colonizes the airways without invading tissues, triggering both Type I (IgE-mediated) and Type III (immune complex-mediated) hypersensitivity reactions.
Causes: Hypersensitivity to Aspergillus fumigatus* antigens.

• Genetic factors: Genetic predisposition plays a role, with associations found with specific HLA-DR alleles (e.g., HLA-DR2 and HLA-DR5) and polymorphisms in genes related to immune response and mucociliary clearance. Certain CFTR mutations in cystic fibrosis patients can also increase susceptibility.

In susceptible individuals, Aspergillus fumigatus spores germinate and colonize the bronchial tree. The host immune system mounts an exaggerated response involving:

1. IgE-mediated hypersensitivity (Type I): High levels of Aspergillus-specific IgE antibodies lead to mast cell degranulation and eosinophil recruitment, contributing to bronchospasm, mucus hypersecretion, and airway inflammation.


2. Immune complex-mediated hypersensitivity (Type III): Aspergillus antigens combine with IgG antibodies to form immune complexes, which deposit in the bronchial walls, activating complement and attracting neutrophils, causing further tissue damage.

ABPA is not rare but often underdiagnosed.

• Prevalence: Occurs in 1-20% of asthmatic patients and 2-15% of cystic fibrosis patients.


• Age distribution: Can affect all ages, but is most commonly diagnosed in young to middle-aged adults (20-50 years).


• Gender distribution: No significant gender predominance.

• Pre-existing asthma (especially severe or difficult-to-treat asthma)
• Cystic fibrosis

• Genetic predisposition (e.g., specific HLA types)

A. Early Symptoms

• Worsening cough


• Increased sputum production


• Exacerbation of asthma symptoms (e.g., increased wheezing, shortness of breath) B. Common Symptoms


• Persistent or recurrent wheezing and shortness of breath (dyspnea)


• Productive cough, often with brown-tinged or mucus plugs (expectoration of "casts" of bronchi)


• Recurrent fever and malaise


• Fatigue


• Weight loss (less common but can occur) C. Advanced Symptoms


• Hemoptysis (coughing up blood)


• Chronic respiratory failure symptoms (e.g., cyanosis, clubbing)


• Severe persistent wheezing refractory to standard asthma treatment D. Emergency Symptoms


• Acute respiratory distress


• Massive hemoptysis

• Inspection: Tachypnea, use of accessory muscles of respiration (during exacerbation), central cyanosis (advanced), digital clubbing (chronic cases).
• Palpation: Increased tactile fremitus over areas of consolidation (rare).
• Percussion: Resonant, or dullness over areas of consolidation/collapse.
• Auscultation: Diffuse polyphonic wheezes, crackles (rales), rhonchi, decreased breath sounds over areas of mucus plugging or collapse.

A. Clinical Assessment
History of asthma or CF, recurrent pulmonary infiltrates on chest imaging, and specific immunological criteria. B. Laboratory Testing
Elevated total IgE, Aspergillus-specific IgE and IgG, peripheral eosinophilia. C. Imaging Studies
Chest X-ray and High-Resolution Computed Tomography (HRCT) of the chest to identify infiltrates, bronchiectasis, and mucus plugging. D. Functional Tests
Spirometry typically shows an obstructive pattern, which may improve with bronchodilators. E. Biopsy Findings
Bronchial biopsies are not routinely performed but can show eosinophilic infiltration, mucus, Charcot-Leyden crystals, and Aspergillus hyphae in the lumen. F. Genetic Testing
Not primary for diagnosis of ABPA, but relevant for identifying underlying CF. G. Differential Diagnosis
Severe asthma, other fungal infections (e.g., chronic pulmonary aspergillosis), chronic eosinophilic pneumonia, allergic bronchopulmonary mycosis (due to other fungi), non-ABPA bronchiectasis, tuberculosis.

Total Serum IgE
Type: Blood Test
Purpose: To assess the overall allergic state; elevated levels are a major diagnostic criterion for ABPA.
Expected Findings: Significantly elevated (>1000 IU/mL, though lower levels with other criteria may suffice).
Interpretation: High levels suggest an allergic component and are a key indicator for ABPA, especially in the context of asthma/CF. Aspergillus fumigatus-specific IgE
Type: Blood Test
Purpose: To confirm sensitization to Aspergillus fumigatus.
Expected Findings: Positive (elevated).
Interpretation: Presence of Aspergillus-specific IgE is a strong indicator of allergic sensitization to the fungus. Aspergillus fumigatus-specific IgG
Type: Blood Test
Purpose: To confirm the presence of an immune response to Aspergillus antigens.
Expected Findings: Positive (elevated).
Interpretation: Elevated Aspergillus-specific IgG suggests exposure and an immune response, indicative of ABPA. Peripheral Eosinophil Count
Type: Blood Test
Purpose: To identify peripheral blood eosinophilia, a hallmark of allergic inflammation.
Expected Findings: Elevated (>500 cells/µL).
Interpretation: High eosinophil counts support the diagnosis of an allergic inflammatory process, typical in ABPA. Sputum Culture/Smear
Type: Sputum Test
Purpose: To detect the presence of Aspergillus hyphae or growth in the airways.
Expected Findings: Positive for Aspergillus fumigatus.
Interpretation: Isolation of Aspergillus fumigatus from sputum in a patient with compatible symptoms and imaging helps confirm the diagnosis.

Chest X-ray
Purpose: Initial screening for pulmonary infiltrates, consolidation, atelectasis, or signs of bronchiectasis.
Typical Findings: Transient or fixed pulmonary infiltrates, tram-line opacities (bronchial wall thickening), ring shadows (bronchiectasis), "finger-in-glove" opacities (mucus-filled bronchi).
Clinical Importance: Helps identify acute flares and chronic changes, guiding the need for further detailed imaging. High-Resolution Computed Tomography (HRCT) of the Chest
Purpose: Detailed visualization of lung parenchyma and airways to confirm and characterize bronchiectasis.
Typical Findings: Central and peripheral bronchiectasis (often cylindrical or varicose), mucus plugging, centrilobular nodules, areas of consolidation, ground-glass opacities, and evidence of previous fibrotic changes.
Clinical Importance: Considered the gold standard for identifying bronchiectasis, especially central bronchiectasis, which is a major diagnostic criterion for ABPA. It also helps assess disease extent and complications.

• Severe asthma: Shares symptoms like wheezing and dyspnea, but ABPA has specific immunological and radiological features.
• Chronic eosinophilic pneumonia: Eosinophilic infiltrates but typically peripheral and non-segmental.

• Bronchiectasis of other etiologies: e.g., post-infectious, alpha-1 antitrypsin deficiency, primary ciliary dyskinesia.
• Pulmonary tuberculosis: Can cause similar infiltrates and bronchiectasis.
• Hypersensitivity pneumonitis: Inflammatory reaction to inhaled organic dusts.

• Bronchiectasis: Permanent dilation of the bronchi, leading to chronic cough and increased susceptibility to infections.
• Lung fibrosis: Irreversible scarring of lung tissue.
• Respiratory failure: Inability of the lungs to adequately oxygenate the blood or remove carbon dioxide.
• Massive hemoptysis: Life-threatening bleeding from the airways.
• Recurrent pulmonary infections: Due to impaired mucociliary clearance and damaged airways.
• Atelectasis: Collapse of part or all of a lung due to mucus plugging.

A. Lifestyle Modifications
Avoidance of known Aspergillus* heavy environments (e.g., compost piles, damp basements).

• Good indoor air quality management. B. Preventive Measures


• Optimal control of underlying asthma or cystic fibrosis.

• Examples: Oral prednisone or prednisolone.

• Examples: Itraconazole, Voriconazole, Posaconazole.

• Examples: Omalizumab (may be used in severe, refractory cases, especially with high IgE levels). D. Surgical Treatment

The prognosis of ABPA is variable. With early diagnosis and consistent treatment, progression to irreversible lung damage can often be halted or significantly slowed. However, recurrences are common, and long-term management is often required. Untreated or poorly managed ABPA can lead to progressive bronchiectasis, lung fibrosis, respiratory failure, and increased mortality.

Primary prevention of ABPA is challenging due to the ubiquitous nature of Aspergillus spores. Secondary prevention focuses on:

• Early diagnosis: Prompt identification of ABPA in patients with asthma or CF presenting with suggestive symptoms or signs.


• Aggressive treatment: To prevent disease progression and irreversible lung damage.


• Monitoring: Regular clinical, immunological, and radiological follow-up to detect exacerbations and adjust treatment.

The following homeopathic remedies have been historically indicated for symptoms associated with Allergic Bronchopulmonary Aspergillosis. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Allergic Bronchopulmonary Aspergillosis.